SCH 57790: a novel M2 receptor selective antagonist.

Area of Science:

• Neuroscience
• Pharmacology
• Medicinal Chemistry

Background:

• Alzheimer's Disease (AD) is associated with a decline in cholinergic neurons.
• Current therapies for AD involve inhibiting acetylcholinesterase to boost acetylcholine levels.
• Presynaptic M2 receptors negatively regulate acetylcholine release in the central nervous system (CNS).

Purpose of the Study:

• To synthesize and characterize a novel compound, SCH 57790, as a potential M2 receptor antagonist.
• To evaluate the potential of M2 receptor blockade as a therapeutic strategy for enhancing cognition in AD.

Main Methods:

• Structure-activity relationship studies of [4-(phenylsulfonyl)phenyl]methylpiperazines.
• Synthesis of 4-cyclohexyl-alpha-[4-[[4-methoxyphenyl]sulfinyl]-phenyl]-1-piperazineacetonitrile (SCH 57790).
• Binding affinity assays using cloned human M2 receptors expressed in CHO cells.
• Functional assays measuring adenylyl cyclase activity inhibition by muscarinic agonists.

Main Results:

• SCH 57790 demonstrated high affinity for human M2 receptors (2.78 nM) with significantly lower affinity for M1 receptors.
• SCH 57790 acted as an antagonist at M2 receptors, blocking oxotremorine-induced inhibition of adenylyl cyclase.
• The compound's selectivity and antagonist properties suggest its utility in M2 receptor research.

Conclusions:

• SCH 57790 is a potent and selective M2 muscarinic receptor antagonist.
• M2 receptor blockade represents a promising therapeutic strategy for increasing acetylcholine release.
• SCH 57790 can be a valuable tool for further investigating M2 receptor blockade in cognitive enhancement.